BMY Stock Slumps 5% After It Scraps Heart Drug Study

2025-11-14 09:00:38

(MENAFN- AsiaNet News)

Bristol Myers Squibb (BMY) announced on Friday that it has decided to halt its late-stage trial evaluating the efficacy and safety of Milvexian when added to conventional antiplatelet therapy in patients following a recent acute coronary syndrome (ACS) event.

Acute coronary syndrome (ACS) is an umbrella term for situations in which blood supplied to the heart muscle is suddenly reduced, usually due to a clot. It includes heart attack, and unstable angina manifesting as sudden severe chest pain.

The decision follows an analysis by an independent data monitoring committee indicating that the trial is unlikely to meet its primary goal, the company stated.

The company will, however, continue its late-stage trials in patients with atrial fibrillation (AF) and for secondary stroke prevention, it added.

Get updates to this developing story directly on Stocktwits.

MENAFN14112025000070015968ID1110344839

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.